Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas/Cardiome’s Vernakalant Wins Advisory Committee Approval In 6-2 Vote

This article was originally published in The Pink Sheet Daily

Executive Summary

Antiarrhythmic’s well-characterized safety profile is a “clear differentiator from other pharmacological therapies,” Astellas exec tells “The Pink Sheet” DAILY.

You may also be interested in...



Cardiome/Astellas Schedule Kynapid Meeting With FDA

Meanwhile, Astellas yanks its Canadian new drug submission for the atrial fibrillation candidate to align its North American regulatory strategy.

Cardiome/Astellas Schedule Kynapid Meeting With FDA

Meanwhile, Astellas yanks its Canadian new drug submission for the atrial fibrillation candidate to align its North American regulatory strategy.

Astellas/Cardiome’s Kynapid “Approvable”

FDA wants more safety data on IV vernakalant.

Related Content

Topics

UsernamePublicRestriction

Register

PS065489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel